Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Zelira Therapeutics well-placed to capitalise on expanding global medicinal cannabis sector

% of readers think this story is Fact. Add your two cents.


Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has strategically consolidated its operations to transfer the leadership of the company to its US-based team, with Dr Oludare Odumosu to assume the role of global managing director.  

With the successful launch of multiple proprietary products in Australia and the US, Zelira will focus on two key priorities for 2021. They are:

  • Leveraging the competitive advantages of its products to generate revenues in global markets; and 
  • Continuing to progress clinical development of selected programs to unlock further value and better inform its marketing strategies. 

Zelira’s international footprint and exposure to international markets mean it is well-positioned to benefit from the rapidly expanding global medicinal cannabis sector.  

HOPE™ products

In late October 2020, Zelira announced that its proprietary cannabinoid medicines, HOPE 1™ and HOPE 2™, were available for prescription to patients in Australia through the Therapeutic Goods Administration’s (TGA) Special Access Scheme and via Authorised Prescribers. 

HOPE™ is part of Zelira’s family of revenue-generating medicinal cannabis formulations. The products consist of two pharmaceutical-grade proprietary formulations developed as pharmaceutical-grade products targeting Autism Spectrum Disorder (ASD) as a disease indication. 

The products are now working their way through the TGA Special Access Scheme, via Authorized Prescribers into the market and patients. 

US distribution 

In December 2020, Zelira announced it has entered into a binding licensing agreement with Alternative Solutions LLC, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC) to manufacture and distribute Zelira’s HOPE™ products. 

Under the terms of the licensing agreement, Zelira will receive licensing fees and ongoing royalties from HOPE™ product sales in Washington DC. 

Washington DC has reciprocity with 32 other states in the US with approved medical cannabis programs – which expands access to patients registered in all the 32 states as they can legally purchase medical cannabis products at an approved dispensary in Washington DC. 

Autism observational trial

Last year, the company launched an Observational Trial for HOPE targeting patients diagnosed with autism, which will be one of the largest of its kind ever undertaken. 

In November 2020, Zelira partnered with Emyria to undertake an observational trial in patients diagnosed with Autism Spectrum Disorder (ASD) treated with the HOPE range of products. 

The 150-patient observational trial will be one of the largest medicinal cannabis studies ever undertaken involving a specific range of products in patients diagnosed with ASD. 

The study design will facilitate strategic engagement with key stakeholders in the autism community and streamline patient access via Emyria’s national network of specialist medical clinics – Emerald Clinics. 

Under the terms of the agreement, Emyria will provide Zelira with real-world longitudinal data collected from ASD patients prescribed a HOPE™ product. 

Data will include patient’s efficacy and safety relating to co-morbidities, concomitant medications, dosing information and patient responses to HOPE™ treatment as measured using standard ASD clinical and behavioural endpoints. 

Subsequent to the announcement, ethics approval was obtained, which has cleared the path for recruitment to commence from January 2021. 

The company was encouraged by the significant number of expressions of interest that have already been lodged, suggestive that recruitment will progress rapidly. 

Future-focused

In February, Zelira was appointed to the board of directors of the National Cannabis Roundtable (NCR) in Washington DC, US and will be represented by Dr Odumosu.

NCR is a non-partisan advocacy group focusing on federal cannabis reform in the US and as part of its reform agenda, it is seeking to remove federal restrictions that prohibit medical research involving cannabis and to allow companies to operate legally in the US-based cannabis industry. 

Zelira is committed to bringing breakthrough therapeutics to market and supports the need for a regulatory framework that will allow the research to expand and grow on a Federal/National level.

Going forward the company‘s commercialisation plans are focused on generating revenues from the multiple products it has launched into the Australian and US market and continuing to launch new product lines. 

The company will also progress additional licensing discussions for HOPE™ and Zenivol™ in the US and look to conclude ongoing negotiations to expand the distribution of these products into other global markets, including Germany and the UK. 

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/945878/zelira-therapeutics-well-placed-to-capitalise-on-expanding-global-medicinal-cannabis-sector-945878.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST


Order by Phone at 888-809-8385 or online at https://www.herbanomic.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.